amifostine ethiofos cytoprotective adjuvant used cancer chemotherapy radiotherapy involving dnabinding chemotherapeutic agents marketed clinigen group trade name ethyol amifostine used therapeutically reduce incidence neutropeniarelated fever infection induced dnabinding chemotherapeutic agents including alkylating agents eg cyclophosphamide platinumcontaining agents eg cisplatin also used decrease cumulative nephrotoxicity associated platinumcontaining agents amifostine also indicated reduce incidence xerostomia patients undergoing radiotherapy head neck cancer amifostine originally indicated reduce cumulative renal toxicity cisplatin nonsmall cell lung cancer however nephroprotection observed probability amifostine could protect tumors could excluded additional data shown amifostinemediated tumor protection clinical scenario unlikely amifostine organic thiophosphate prodrug hydrolysed vivo alkaline phosphatase active cytoprotective thiol metabolite selective protection nonmalignant tissues believed due higher alkaline phosphatase activity higher ph vascular permeation normal tissues amifostine administered intravenously subcutaneously reconstitution normal saline infusions lasting less minutes decrease risk adverse effects patient wellhydrated prior administration inside cells amifostine detoxifies reactive metabolites platinum alkylating agents well scavenges free possible effects include accelerated dna induction cellular inhibition alteration gene modification enzyme amifostine believed radioprotect normal tissue via warburgtype common side effects amifostine include hypocalcemia diarrhea nausea vomiting sneezing somnolence hiccups serious side effects include hypotension found patients erythema multiforme syndrome toxic epidermal necrolysis immune hypersensitivity syndrome erythroderma anaphylaxis loss consciousness rare contraindications receiving amifostine include hypersensitivity amifostine aminothiol compounds like ethyol contains mannitol httpsenwikipediaorgwikiamifostine